Invesco · 2005-06-23 成立 · 规模、费率、NAV、资金流、完整持仓和风险收益使用各自可追溯公开源。
| 日期 | 估算净流 | 申购 / 销售 | 赎回 | 净资产 | 口径 |
|---|---|---|---|---|---|
| 2026-07-31 | -$1.3M | — | — | $356.1M | 每日估算 |
| 2026-07-30 | -$81.4M | — | — | $356.1M | 每日估算 |
| 2026-07-27 | +$80.9M | — | — | $437.5M | 每日估算 |
| 2026-07-26 | -$82.0M | — | — | $356.1M | 每日估算 |
| 2026-04-30 | -$70.6M | $0 | $70.6M | $333.1M |
| 持仓 | 资产类别 | 数量 | 市值 | 权重 |
|---|---|---|---|---|
Invesco Private Prime Fund Invesco Private Prime Fund | STIV | 40,176,636 | $40.2M | 12.06% |
Pfizer Inc. Pfizer Inc. | EC | 650,394 | $17.4M | 5.21% |
Johnson & Johnson Johnson & Johnson | EC | 71,697 | $16.5M | 4.95% |
AbbVie Inc. AbbVie Inc. | EC |
行情与风险截至 2026-07-30；NAV 的发布时间可能和交易所收盘错位。完整持仓是延迟监管披露，不代表当前盘中组合。
已使用：nasdaq_etf_screener、yahoo_chart、yahoo_quote_summary、sec_nport。缺口标记：nav_timestamp_unverified、category_reclassified_by_current_taxonomy。
| SEC 月度 |
| 2026-03-31 | -$2.0M | $2.1M | $4.1M | — | SEC 月度 |
| 2026-02-28 | +$4.5M | $9.8M | $5.4M | — | SEC 月度 |
| 77,267 |
| $16.3M |
| 4.90% |
Amgen Inc. Amgen Inc. | EC | 46,101 | $16.0M | 4.79% |
Eli Lilly and Co. Eli Lilly and Co. | EC | 16,954 | $15.8M | 4.76% |
Gilead Sciences, Inc. Gilead Sciences, Inc. | EC | 119,553 | $15.6M | 4.70% |
Merck & Co., Inc. Merck & Co., Inc. | EC | 142,422 | $15.5M | 4.67% |
Invesco Private Government Fund Invesco Private Government Fund | STIV | 15,472,068 | $15.5M | 4.64% |
Abbott Laboratories Abbott Laboratories | EC | 154,072 | $14.0M | 4.20% |
Travere Therapeutics, Inc. Travere Therapeutics, Inc. | EC | 316,568 | $13.3M | 4.00% |
Corcept Therapeutics Inc. Corcept Therapeutics Inc. | EC | 267,966 | $12.5M | 3.74% |
Ligand Pharmaceuticals Inc. Ligand Pharmaceuticals Inc. | EC | 51,702 | $11.9M | 3.56% |
United Therapeutics Corp. United Therapeutics Corp. | EC | 20,645 | $11.8M | 3.54% |
Liquidia Corp. Liquidia Corp. | EC | 291,200 | $11.4M | 3.43% |
Jazz Pharmaceuticals PLC Jazz Pharmaceuticals PLC | EC | 56,229 | $11.4M | 3.43% |
Harmony Biosciences Holdings, Inc. Harmony Biosciences Holdings, Inc. | EC | 346,778 | $10.8M | 3.25% |
Ocular Therapeutix, Inc. Ocular Therapeutix, Inc. | EC | 1,091,691 | $10.2M | 3.07% |
ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. | EC | 127,446 | $10.1M | 3.04% |
Bristol-Myers Squibb Co. Bristol-Myers Squibb Co. | EC | 158,707 | $9.6M | 2.89% |
Innoviva, Inc. Innoviva, Inc. | EC | 417,402 | $9.6M | 2.88% |
Biogen Inc. Biogen Inc. | EC | 50,084 | $9.5M | 2.85% |
Viatris Inc. Viatris Inc. | EC | 608,509 | $9.1M | 2.73% |
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc. | EC | 12,647 | $8.9M | 2.68% |
Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals, Inc. | EC | 183,401 | $8.8M | 2.64% |
Amneal Pharmaceuticals, Inc. Amneal Pharmaceuticals, Inc. | EC | 666,857 | $8.6M | 2.58% |
Tarsus Pharmaceuticals, Inc. Tarsus Pharmaceuticals, Inc. | EC | 130,320 | $8.3M | 2.49% |
Prestige Consumer Healthcare Inc. Prestige Consumer Healthcare Inc. | EC | 142,108 | $8.0M | 2.40% |
Perrigo Co. PLC Perrigo Co. PLC | EC | 669,151 | $7.9M | 2.38% |
Amphastar Pharmaceuticals, Inc. Amphastar Pharmaceuticals, Inc. | EC | 353,313 | $7.8M | 2.33% |
Collegium Pharmaceutical, Inc. Collegium Pharmaceutical, Inc. | EC | 216,401 | $7.3M | 2.19% |
Invesco Government & Agency Portfolio, Institutional Class Invesco Government & Agency Portfolio, Institutional Class | STIV | 162,338 | $162,338 | 0.05% |
OmniAb, Inc., Rts., expiring 2027-11-02 OmniAb, Inc., Rts., expiring 2027-11-02 | EC | 39,023 | $0 | 0.00% |
OmniAb, Inc., Rts., 2027-11-02 OmniAb, Inc., Rts., 2027-11-02 | EC | 39,023 | $0 | 0.00% |